

1ST Biotherapeutics Partners with Lilly TuneLab to Accelerate Small Molecule Pipeline

- Enhancing R&D efficiency in hit discovery and lead optimization using Lilly's proprietary AI models
- Advancing predictive ADMET accuracy across neurodegeneration and oncology therapeutic programs



SEOUL, South Korea – May 7, 2026 – 1ST Biotherapeutics (1STBIO) announced today an agreement with Eli Lilly and Company (Lilly) that provides access to Lilly TuneLab, a collaborative drug discovery platform that enables biotech companies to utilize AI models trained on research data contributed by Lilly and other TuneLab partners.

This collaboration is focused on applying AI-driven modeling to early-stage drug discovery workflows, including hit identification and lead optimization, supporting 1STBIO's small molecule pipeline programs in neurodegeneration and oncology.

Since its inception in 2016, 1STBIO has established a robust drug discovery framework integrating Medicinal Chemistry (MedChem) with Artificial Intelligence (AI). The company has independently curated high-precision, "AI-Ready" ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) datasets specifically designed for integration into AI modeling workflows.

By applying Lilly's AI models through the TuneLab platform within its early discovery workflow, 1STBIO aims to enhance the accuracy of ADMET predictions and improve the efficiency of hit-to-lead progression across its pipeline programs, while maintaining proprietary data within a

secure environment.

“Participation in Lilly TuneLab provides an important opportunity to further strengthen 1STBIO’s AI-enabled, data-driven discovery capabilities,” said Jamie Jae-Eun Kim, CEO of 1STBIO. “By combining Lilly’s advanced AI technology with 1STBIO’s research expertise, we aim to strengthen our discovery competitiveness and achieve meaningful translational and commercial outcomes.”

About 1ST Biotherapeutics, Inc.

1ST Biotherapeutics is a science-driven biopharmaceutical company focused on the development of breakthrough therapies in neurodegenerative diseases, immuno-oncology, and rare diseases. Founded in 2016, the Company has developed a pipeline of investigational drugs aimed at addressing critical unmet medical needs. The Company is headquartered in Yongin, South Korea. For more information, visit <http://www.1stbio.com>